After years of inactivity, the Drug Enforcement Administration has finally taken steps toward approving more suppliers of medical marijuana for scientific research, but its plan is raising questions about the role that the agency would play.

In a notice issued late last week, the DEA proposed a new rule that would have the agency take on a host of new responsibilities by inserting itself into the supply chain. Specifically, the DEA would control distribution by purchasing crops from manufacturers and shipping them to marijuana researchers. The DEA explained such a step would be necessary to remain in compliance with international treaties.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy